title: Efficacy and safety of collagenase clostridium histolyticum injection for Dupuytren contracture: short-term results from 2 open-label studies.
abstract: OBJECTIVE
  The JOINT I (United States) and JOINT II (Australia and Europe) studies evaluated the efficacy and safety of collagenase clostridium histolyticum (CCH) injection for the treatment of Dupuytren contracture.
  
  
  METHODS
  Both studies used identical open-label protocols. Patients with fixed-flexion contractures of metacarpophalangeal (MCP) (20° to 100°) or proximal interphalangeal (PIP) joints (20° to 80°) could receive up to three 0.58-mg CCH injections per cord (up to 5 total injections per patient). We performed standardized finger extension procedures to disrupt injected cords the next day, with follow-up 1, 2, 6, and 9 months thereafter. The primary end point (clinical success) was reduction in contracture to within 0° to 5° of full extension 30 days after the last injection. Clinical improvement was defined as 50% or more reduction from baseline contracture.
  
  
  RESULTS
  Dupuytren cords affecting 879 joints (531 MCP and 348 PIP) in 587 patients were administered CCH injections at 14 U.S. and 20 Australian/European sites, with similar outcomes in both studies. Clinical success was achieved in 497 (57%) of treated joints using 1.2 ± 0.5 (mean ± SD) CCH injections per cord. More MCP than PIP joints achieved clinical success (70% and 37%, respectively) or clinical improvement (89% and 58%, respectively). Less severely contracted joints responded better than those more severely contracted. Mean change in contracture was 55° for MCP joints and 25° for PIP joints. With average contracture reductions of 73% and improvements in range of motion by 30°, most patients (92%) were "very satisfied" (71%) or "quite satisfied" (21%) with treatment. Physicians rated change from baseline as "very much improved" (47%) or "much improved" (35%). The CCH injections were well tolerated, causing no tendon ruptures or systemic reactions.
  
  
  CONCLUSIONS
  Collagenase clostridium histolyticum was an effective, minimally invasive option for the treatment of Dupuytren contracture of a broad range of severities. Most treated joints (625 of 879) required a single injection. Treatment earlier in the course of disease provided improved outcomes.
  
  
  METHODS
  Therapeutic IV.
authors.affiliation: Department of Hand Surgery, Uppsala University Hospital, Uppsala, Sweden. jwitthaut@schoen-kliniken.de
authors.forename: Jörg
authors.initials: J
authors.lastname: Witthaut
authors.forename: Graeme
authors.initials: G
authors.lastname: Jones
authors.forename: Nebojsa
authors.initials: N
authors.lastname: Skrepnik
authors.forename: Harvey
authors.initials: H
authors.lastname: Kushner
authors.forename: Anthony
authors.initials: A
authors.lastname: Houston
authors.forename: Tommy R
authors.initials: TR
authors.lastname: Lindau
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D047009:Hathewaya histolytica / Q000201:enzymology*; D004387:Dupuytren Contracture / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D003012:Microbial Collagenase / Q000008:administration & dosage*; D008875:Middle Aged; D017060:Patient Satisfaction; D016059:Range of Motion, Articular; D019233:Retreatment; D016896:Treatment Outcome
chemical_list: D003012:Microbial Collagenase